Health experts say that boosters are likely to be needed eventually and that more data should be available in the next several weeks. Read Article
The decision to expand the emergency use of both the Pfizer-BioNTech and Moderna vaccines is meant to help transplant recipients and others whose immune systems are similarly compromised. Read Article
Dan Barouch, Harvard Medical School professor and head of Beth Israel Deaconess’ Center for Virology and Vaccine Research, was awarded Harvard’s George Ledlie Prize for his work on one of three vaccines against COVID-19 approved for use in the U.S. Read Article
“This study was conducted as a real-world efficacy study in one of the most challenging epidemiologic settings,” said Dr. Dan Barouch, a virologist at Beth Israel Deaconess Medical Center in Boston who has led some studies for J. & J. Read Article
Dan Barouch, told ABC News in late May that the pharmaceutical companies have an economic incentive and that a decision on booster shots should be made based on public health solely and not on economic incentives of the companies. Read Article
The Johnson & Johnson vaccine appears to provide strong protection against the Delta variant that not only doesn’t wane over time but seems to grow stronger. See Article
The Johnson & Johnson coronavirus vaccine provides immunity that lasts at least eight months, and it appears to provide adequate protection against the worrying Delta variant, the company said in a statement Thursday night. Read Article
Johnson & Johnson announced that its COVID-19 vaccine “”generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.” The vaccine was developed in a collaboration between Johnson & Johnson and BIDMC, led by Dan Barouch. Read Article
NYT
HMS
wsj
atlantic
ABCNEWS
CNN
Boston Globe